Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cyclerion Therapeutics, Inc.

2.53
+0.06002.43%
Post-market: 2.530.00000.00%19:03 EDT
Volume:7.78K
Turnover:19.80K
Market Cap:6.86M
PE:-2.08
High:2.65
Open:2.65
Low:2.49
Close:2.47
Loading ...

Company Profile

Company Name:
Cyclerion Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
1
Office Location:
245 First Street, Riverview II,18th Floor,Cambridge,Massachusetts,United States
Zip Code:
02142
Fax:
617 890 6595
Introduction:
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Peter M. Hecht
Chief Executive Officer and Director
Amy Schulman
Director
George Conrades
Director
Kevin Churchwell
Director
Marsha H. Fanucci
Director
Michael Mendelsohn
Director
Ole Isacson
Director
Stephanie Lovell
Director
Terrance McGuire
Director

Shareholders

Name
Position
Peter M. Hecht
Chief Executive Officer and Director
William Huyett
Chief Financial Officer
Mark G. Currie
President